Content about Douglas Michels

November 30, 2012

OraSure prepares nationwide TV promotion campaign for in-home HIV test

HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.

BETHLEHEM, Pa. — HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.

The TV campaign will be timed to coincide with World AIDS Day on Saturday and will air on MTV, A&E, BET, E!, Bravo and Logo, as well as on the NBC reality show "The Voice" on Dec. 17.

May 16, 2012

FDA advisory committee recommends OTC availability of HIV test

OraSure Technologies on Tuesday announced that the Food and Drug Administration's Blood Products Advisory Committee recommended that the OraQuick In-Home HIV test be made available without a prescription.

BETHLEHEM, Pa. — OraSure Technologies on Tuesday announced that the Food and Drug Administration's Blood Products Advisory Committee recommended that the OraQuick In-Home HIV test be made available without a prescription.

“There was broad support expressed by the HIV community at [the] meeting, and we look forward to continuing our work with them in the fight against HIV," stated OraSure president and CEO Douglas Michels. "We believe the OraQuick In-Home HIV Test will make a valuable contribution in this fight.”

April 5, 2012

FDA advisory committee to review OTC availability of HIV test in May

OraSure Technologies on Wednesday announced that the Food and Drug Administration's Blood Products Advisory Committee will consider making its OraQuick Rapid HIV-1/2 test available over the counter on May 15.

BETHLEHEM, Pa. — OraSure Technologies on Wednesday announced that the Food and Drug Administration's Blood Products Advisory Committee will consider making its OraQuick Rapid HIV-1/2 test available over the counter on May 15.

At the meeting, OraSure will present its consumer-usage studies — approximately 5,800 subjects were enrolled and tested in this phase across 20 states, the company said, which helped identify more than 100 previously undiagnosed individuals.